T1	Participants 173 277	elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies
T2	Participants 675 778	One hundred and fifty-five patients were randomized, 144 were evaluable for safety and 142 for response
